PMR, Competitive Landscape, Competitive Intelligence & KOL

Pharmaceutical, biotech and life sciences companies are able to capitalize the immense secondary data source for smart, well-informed decision-making on commercial operations, sales and marketing to segment their targets, match them to optimal channels and develop effective messages for internal and external stakeholders. Secondary data offers little in the way of insights to help pharma companies understand why a target group is behaving a particular way or which channels it prefers. Making assumptions about behaviors and channels based purely on secondary data can lead to inappropriate tactics, missed targets and wasted resources.

However, Thelansis supporting their clients with a newer emerging integrated approach, in which combination of primary market research (PMR) and secondary data analytics yield robust insights than standalone of each discipline and help our clients in many areas; new product development, identification of unmet need, competitive intelligence (CI) and many more. Thelansis Primary market research (PMR) scoop out the answers for the most appropriate target, preferable channels to reach the target effectively, perception of influencers/ Key Opinion Leaders (KOLs), product fit into competitive landscape, clinical endpoints covering unmet needs and beyond.

Primary market research (PMR) bridges the gap to information generated through the secondary research, where secondary data presents a snapshot of what is happening, such as the highest prescriber in a class, early adopters vs. laggards, etc. Secondary source data, however, cannot explain why a specific physician or group of physicians is prescribing or not prescribing a product. Primary research can uncover the reason behind the data.

Tuberous Sclerosis Complex (TSC) - Market Outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 

Indication name: Tuberous Sclerosis Complex (TSC)

Tuberous Sclerosis Complex (TSC), Thelansis Epidemiology study reflects there is 1 in 6,000 newborns in the United States. Approximately 40,000 to 80,000 people in the United States have tuberous sclerosis. The prevalence in Europe is estimated to be approximately 1 in 25,000 to 1 in 11,300. As many as 2 million people worldwide are believed to have the disorder.

Competitive landscape of TSC includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of TSC across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

TSC Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing , Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Tuberous sclerosis complex (TSC) Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 

S. N.        Asset        Company        Stage

1        Drug: RAD001        Novartis Pharmaceuticals        Phase 3

2        Drug: Sirolimus 0.2%        Aucta Pharmaceuticals, Inc        Phase 2

3        Drug: NPC-12G gel        Nobelpharma        Phase 3

4        Drug: Ganaxolone        Marinus Pharmaceuticals        Phase 2

5        Drug: Aspirin        Shijiazhuang Yiling Pharmaceutical Co. Ltd        Phase 2

6        Drug: Rapamune        Pfizer        Phase 1

7        Drug: Vatiquinone        PTC Therapeutics        Phase 3

8        Drug: TAK-935        Takeda        Phase 2

9        Drug: Circadin 2/5/10 mg        Neurim Pharmaceuticals Ltd.        Phase 3

10        Drug: TAK-935        Ovid Therapeutics Inc.        Phase 2

Alport Syndrome – Market Outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

Report Summary:

Thelansis “Alport Syndrome (AS) - Market outlook, Epidemiology, Market Forecast and Competitive Landscape - 2018 To 2030 ”  this report provides a comprehensive study of the disease area landscape and changing market dynamics with  respect to the current & future market events for the 8 MM countries (USA, EU5, Japan & China).

The report provides a comprehensive view of disease events, classification, severity level, stages, identified and emerging biomarkers, progression, manifestations, symptoms, risk factors, pathogenesis, genetic basis and treatment guidelines at country level.

Disease overview:

Alport syndrome is an inherited progressive form of glomerular disease that is often associated with sensorineural hearing loss and ocular defects. The primary abnormality arises from mutations in genes encoding the type IV collagen protein family. This syndrome is a genetically heterogeneous disease having different mutations and forms of inheritance: X-linked (mutations in COL4A5 gene), autosomal recessive (homozygous or compound heterozygous mutations in COL4A3 or COL4A4 genes) and autosomal dominant.

Epidemiology:

The total number of Alport syndrome increased from 128,924 in 2018 to 182,305 by 2030. The USA comprises of ~38 of the total diagnosed cases of AS followed by China, EU5 and Japan. ~80% cases had typical glomerular basement membrane (GBM) changes of AS, ~10% patients initially had pathology features of diffuse thinning of the GBM only, 14% patients showed pathology of focal segmental glomerulosclerosis (FSGS).

Read more: Alport Syndrome – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

Market Scenario:

Current clinical practice recommendations for delaying end stage renal disease in patients with Alport syndrome focus on early introduction of RAAS inhibitors to suppress urinary protein excretion.

KOL insights: KOLs across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Competitive Landscape:

Considering Alport syndrome is an excellent model of CKD with proteinuria and fibrosis, orphan drug designation with premium pricing benefits, number of patients to be treated will be substantial and finally s no approved treatment several drug candidates are in Phase II and II/ III stages of development by various companies.

Market Forecasting: Thelansis’ research team expects the Alport syndrome market potential for 2030 at $X.XXB in 8MM countries. Out of this market, 68.5% sales are expected to be contributed from the US market whereas XX.X% is expected to come from EU-5. Japan and China are expected to contribute XX.X% and X.X% respectively.

* Alport syndrome current market stands at $XXXX.XM which is expected to grow from 2019 to 2024 at a CAGR of X.X%. Majorly this is expected because of expected approvals of pharmacotherapies in the space.

Contact Us:

About Thelansis: As the name depicts Thelansis is specialized in “Therapy Area Landscape Analysis” along with market intelligence and consultancy that supports pharmaceutical, biotechnology, and diagnostics companies to successfully prepare, launch, and commercialize their products. Our Syndicated primary market research reports include Market Insight, Pipeline Insight, Product Insight, Specialized Reports, Indication Outlook and Market Access Reports. Ask for our report offerings, and Indication specific sample pages by sharing your email ID with us at, p.potdar@thelansis.com.

Peeyush Potdar

Delivery Head:

Email: p.potdar@thelansis.com

Visit us at http://www.thelansis.com/

Delivery office

B-1030, C Wing

Vrindavan tech village Marathahalli

Outer ring road, Bangalore- 560037

Sales office

183-Asylum Street Hartfort, CT-06103, USA

Telephone

USA +1-302-380-3552, India +91-9899921259

Email

clientsupport@thelansis.com, sales@thelansis.com

What is Competitive Intelligence (CI)

Biopharmaceutical industry is a highly competitive landscape. Competition is intense and all the companies develop and compete for market share for each indication, condition, and therapeutic area. Since majority of the pharmaceuticals are developed for specific indications with limited patent expiry shelf life, companies are continuously investing into research and development (R&D) to discover new biologics/drugs or entering into partnerships/collaborations, acquisitions, and mergers.

Competitive Intelligence (CI) helps drug developers/companies to understand its competitive environment, challenges, and opportunities. CI is a process of defining, gathering, and analyzing information regarding competition, customers and events in the industry and distributing the valuable insights internally to help make informed business decisions. CI allows drug developers to continuously learn from theirs as well as others’ failures and successes.

Key uses of CI

·         Portfolio Analysis

·         KOLs tracking

·         New Opportunities

·         Competitor Strengths/Weaknesses

An Introduction to Market Research & Market Forecasting

Market Research (MR) is intelligent prerequisite for any product-based companies in the pharmaceutical industry. It includes various forms of research namely primary (PMR) and secondary research.

Primary Market Research would include reaching out to people/groups via calls, emails, or online surveys as well as group discussions or interviews. Market Research studies are conducted with specific objectives to estimate potential market size for a new product, consumer perception of an existing product in the market or understand reasons for failure of a product in the market. MR studies also helps in understanding competitors’ strengths, weaknesses, and market share/sales/probable sales volume for a specific product or therapeutic areas. PMR data that is collected first-hand for a specific research purpose.

It is defined as a procedure used by researchers to gather data directly, rather than depending on data composed from previously done research. Primary research is solely carried out to address a certain problem, which requires in-depth analysis. There are two types of research: Primary Research & Secondary Research.

Market Forecasting

Forecasting is an important component of decision making process, market sizing, and all the marketing activities. A market forecasting is vital part of market analysis and projects the future numbers, trends, and characteristics in the target market. Forecasting serves as a primary tool for sales teams and sales managers to help with data and insights about projected sales volumes, costs, market shares and other areas of sales or marketing planning  and programmes. Total market forecasting helps companies predict or project its own product sales, competitor’s sales as well as market evolution.

What are KOL Insights or KOL Opinions

Key Opinion Leaders are members of a community whose advice is respected by peers and others in their respective fields. Generally, KOLs are physicians and academicians. However, majority of drug developers choose to include a range of strategic partners and prefers the term, “experts”. Experts are mostly experienced physicians, but may include the following like patient advocacy groups, academics, researchers, and upcoming stars (rising stars: gained expertise in specific disease area) within therapy area.

Experts/KOLs helps companies understand and identify target research areas as they are on the front lines of patient care. Also, experts provide KOL insights and guidance in each step of drug development process – clinical trials (influence trial designs); Approvals (advise on regulatory pathways); Post Approval (builds product awareness in the specialities and medical community); distribution (experts networks can be leveraged to increase and spread awareness of new therapy; discuss new findings through scientific conferences and articles publication).

In short, KOLs help in the following:

• Identifying target customers
• Generate sales
• Enhance companies and products reach
• Increases brand awareness
• Early life-cycle planning
• Conduct RWE studies